Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antidepressants/obezita
Odkaz sa uloží do schránky
Strana 1 od 46 výsledky
Treating obesity with muscarinic receptor M.sub.1 antagonists
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not Applicable
FIELD OF THE INVENTION
The present invention relates to the treatment of obesity and the facilitation of weight loss by administration of a selective M.sub.1 muscarinic receptor (M.sub.1R)
Oxadiazole benzenesulfonamides as selective .beta..sub.3 Agonist for the treatment of Diabetes and Obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2
Substituted sulfonamides as selective .beta..sub.3 agonists for the treatment of diabetes and obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2
Substituted sulfonamides as selective .beta..sub.3 agonists for the treatment of diabetes and obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2
Substituted phenyl sulfonamides as selective .beta. 3 agonists for the treatment of diabetes and obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2
Substituted sulfonamides as selective .beta.-3 agonists for the treatment of diabetes and obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2
Thiazole benzenesulfonamides as .beta.3 agonists for treatment of diabetes and obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2
Selective .beta..sub.3 agonists for the treatment of diabetes and obesity
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
RELATED APPLICATIONS
This application claims priority to U.S. provisional application Ser. No. 60/006,070, filed Oct. 24, 1995, and to U.S. provisional application Ser. No. 60/004,332, filed Sep. 26, 1995.
BACKGROUND OF THE INVENTION
.beta.-Adrenoceptors have been subclassified as .beta..sub.1 and
Intermediate for antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta [a]naphthalene
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
This application is a divisional of application Ser. No. 10/131,987, filed on Apr. 25, 2002, now U.S. Pat. No. 6,525,075, filed on Feb. 25, 2003 which claims priority from provisional application Ser. No. 60/287,449, filed on Apr. 30, 2001, the entire disclosure of which
Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Major depressive disorder affects an estimated 340 million people worldwide. According to the World Health Organization, depression is the fourth greatest public health problem. If left untreated, the effects of depression can be devastating, robbing people of the energy or motivation to perform
Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
Antidepressant azaheterocyclymethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-Dioxino[2,3-f]quinoxaline
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15 20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
